A Phase 3 interventional study of OxyNorm Capsules and Morphine tablet in Postoperative Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-02-26.
Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing oxycodone in Pain, Postoperative — 5 open to participants now, 7 under way, 1 of them phase 3. Oxycodone · Pain, Postoperative.
Among the 32 studies testing oxycodone in Pain, Postoperative, this one is the 8th largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 8th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →5 of the 32 studies testing oxycodone in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Tianjin First Central Hospital · Sites in China
Ages 18–80
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only
Murdoch Childrens Research Institute · Sites in Australia
Ages 6–18
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 4 · Phase 4 18
First in 2005; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 126 across the 32 interventional studies. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mundipharma (China) Pharmaceutical Co. Ltd, one of the names counted as Mundipharma. Under that name alone:
Mundipharma (China) Pharmaceutical Co. Ltd is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
Mundipharma has 3 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
3 of the studies testing oxycodone in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05548582Johns Hopkins UniversityReduced Opioid Prescription After Laparoscopic Hysterectomy | 2026-12-31 |
| NCT06338865Cedars-Sinai Medical CenterShort Title: Standard vs. Lower Pressure Pneumoperitoneum | 2027-04 |
| NCT03105518Brigham and Women's HospitalPredictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing oxycodone in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The efficacy and safety of oxycodone capsules compared with morphine tablets in hospitalized patients with moderate to severe pain following surgery.
To evaluate the efficacy and safety of oxycodone immediate-release capsules compared with morphine immediate-release tablets in hospitalized patients with moderate to severe pain following surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To determine the efficacy and safety of OxyNorm Capsules.
Drug: OxyNorm Capsules
To determine the efficacy and safety of Morphine tablet.
Other: Morphine tablet
dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
Also known as: OxyNorm
dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
Also known as: Morphine
Visual Analogue Scale (VAS) in Resting Stage at 6hour (6hour±20 Minutes After Administration of First Dose)
To measure resting VAS at 6h(±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bad as you can image at resting stage
Time frame: Baseline and 6h (±20min)
VAS in Both Resting and Coughing Stage at 0.5h, 2h and 24h After Administration of First Dose
To measure the resting and coughing VAS as 0.5h (±5min), 2h (±10min) and 24h (±20min) after administration of first dose, assessing the intensity of pain and to conduct inter-group comparison
Time frame: Baseline,0.5h (±5min), 2h (±10min) and 24h (±20min)
The Use of Rescue Analgesics During the 24-hour Observation Period
To calculate the subject who used rescue analgesics during the 4 dose interval within the 24-hour observation period and to conduct inter-group comparison
Time frame: 24 hours after the first dose.
VAS in Coughing Stage at 6h (6h±20min After Administration of First Dose)
To measure coughing VAS at 6h (±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bed as you can image applicable for both resting and coughing stage
Time frame: Baseline and 6h (±20min)
Sleeping Quality Assessment
To assess Sleeping quality assessment during 24 hours after administration of first dose and to conduct inter-group comparison Sleeping quality scale 1. Very Good 2. Good 3. Fair 4. Bad 5. Very Bad
Time frame: 24 hours after administration of first dose
Satisfaction With Pain Control
To assess the Satisfaction with pain control during 24 hours after administration of first dose and to conduct inter-group comparison 1. Very Satisfied 2. Satisfied 3. Fair 4. Not Satisfied 5. Not Satisfied at all
Time frame: 24 hours after administration of first dose
Comparison of the Total Amount of Study Drugs Used During the 24 Hours
To calculate the total amount of study drugs used during the 24 hours and to conduct inter-group comparison The study drug administration is average 6 hours,so the maximal is use 4 times in 24 hours. The investigate to evaluate if the subject need to take the 2nd, 3rd and 4th dose after the mandatory the 1st dose.
Time frame: 24 hours after administration of first dose
This study is a randomized, double blind, double dummy, multicenter, parallel group, comparative study to compare the efficacy and safety of oxycodone capsule versus morphine tablet. The subject recruited from hospitalized patients poor with moderate to severe pain following surgery. The duration of the study from 2011 Jul to 2011 Dec.
| Milestone | OxyNorm Capsules | Morphine Tablet |
|---|---|---|
| Started | 117 | 117 |
| Completed | 117 | 117 |
| Not completed | 0 | 0 |
To measure resting VAS at 6h(±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bad as you can image at resting stage
| units on a scale | OxyNorm Capsules | Morphine Tablet |
|---|---|---|
| baseline of Visual Analogue Scale | 46.21 ± 9.53 | 45.48 ± 7.94 |
| 6th hours Visual Analogue Scale | 20.21 ± 15.66 | 19.94 ± 15.68 |
To measure the resting and coughing VAS as 0.5h (±5min), 2h (±10min) and 24h (±20min) after administration of first dose, assessing the intensity of pain and to conduct inter-group comparison
| units on a scale | OxyNorm Capsules | Morphine Tablet |
|---|---|---|
| Resting baseline of Visual Analogue Scale | 46.21 ± 9.53 | 45.48 ± 7.96 |
| Resting visual analogue scale before first dose | 46.21 ± 9.53 | 45.48 ± 7.96 |
| Resting VAS 0.5 hour after first dose | 29.87 ± 13.59 | 29.80 ± 12.39 |
| Resting VAS 2 hours after first dose | 20.58 ± 14.40 | 20.89 ± 12.70 |
| Resting VAS 24 hours after first dose | 9.73 ± 12.52 | 9.75 ± 11.19 |
| Coughing baseline of Visual Analogue Scale | 55.16 ± 12.15 | 53.91 ± 10.39 |
| Coughing visual analogue scale before first dose | 55.20 ± 12.12 | 53.91 ± 10.39 |
| Coughing VAS 0.5 hour after first dose | 39.21 ± 16.56 | 37.96 ± 13.61 |
| Coughing VAS 2hours after first dose | 29.68 ± 17.91 | 29.30 ± 13.76 |
| Coughing VAS 24hours after first dose | 17.11 ± 13.51 | 16.27 ± 12.58 |
To calculate the subject who used rescue analgesics during the 4 dose interval within the 24-hour observation period and to conduct inter-group comparison
| Participants | OxyNorm Capsules | Morphine Tablet |
|---|---|---|
| First dose interval(0-6h) | 7 | 5 |
| Second dose interval(7-12h) | 8 | 2 |
| Third dose interval(13-18) | 1 | 0 |
| Fourth dose interval(19-24h) | 3 | 2 |
To measure coughing VAS at 6h (±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bed as you can image applicable for both resting and coughing stage
| units on a scale | OxyNorm Capsules | Morphine Tablet |
|---|---|---|
| Visual Analogue Scale of baseline coughing | 55.16 ± 12.15 | 53.91 ± 10.39 |
| Visual Analogue Scale after 6hours coughing | 28.81 ± 17.58 | 28.15 ± 16.79 |
To assess Sleeping quality assessment during 24 hours after administration of first dose and to conduct inter-group comparison Sleeping quality scale 1. Very Good 2. Good 3. Fair 4. Bad 5. Very Bad
| Participants | OxyNorm Capsules | Morphine Tablet |
|---|---|---|
| Very Good | 31 | 36 |
| Good | 38 | 48 |
| Fair | 38 | 26 |
| Bad | 5 | 2 |
| Very Bad | 1 | 1 |
To assess the Satisfaction with pain control during 24 hours after administration of first dose and to conduct inter-group comparison 1. Very Satisfied 2. Satisfied 3. Fair 4. Not Satisfied 5. Not Satisfied at all
| Participants | OxyNorm Capsules | Morphine Tablet: |
|---|---|---|
| Very Satisfied | 38 | 43 |
| Satisfied | 54 | 58 |
| Fair | 19 | 12 |
| Not Satisfied | 2 | 0 |
| Not Satisfied at all | 0 | 0 |
To calculate the total amount of study drugs used during the 24 hours and to conduct inter-group comparison The study drug administration is average 6 hours,so the maximal is use 4 times in 24 hours. The investigate to evaluate if the subject need to take the 2nd, 3rd and 4th dose after the mandatory the 1st dose.
| mg | OxyNorm Capsules | Morphine Tablet |
|---|---|---|
| Comparison of the Total Amount of Study Drugs Used During the 24 Hours | 18.50 ± 10.37 | 39.82 ± 21.79 |
Collected over The protocol requires safety follow up until 24 hours after the last study medication dosing. So the longest time one subject in the study is 48 hours after the 1st study medication doing, include taking full of the 4 times dosing(intotal 24 hours) following by safety follow up for 24 hours.. Non-serious events are listed at a 0.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OxyNorm Capsules | 0/117 (0%) | 0/117 (0%) | 35/117 (29.9%) |
| Morphine Tablet | 0/117 (0%) | 0/117 (0%) | 35/117 (29.9%) |
| Event | OxyNorm Capsules | Morphine Tablet |
|---|---|---|
| NauseaGastrointestinal disorders | 15/117 | 14/117 |
| VomitingGastrointestinal disorders | 7/117 | 7/117 |
| DizzinessNervous system disorders | 7/117 | 6/117 |
| abdominal distensionGastrointestinal disorders | 3/117 | 5/117 |
| blood glucose increaseBlood and lymphatic system disorders | 1/117 | 3/117 |
| backacheMusculoskeletal and connective tissue disorders | 2/117 | 0/117 |
| postoperative infectionInfections and infestations | 2/117 | 2/117 |
| headacheNervous system disorders | 2/117 | 1/117 |
| serum creatinine increaseBlood and lymphatic system disorders | 2/117 | 2/117 |
| leucocyte count increaseBlood and lymphatic system disorders | 0/117 | 2/117 |
| Age, Continuous(years) | OxyNorm Capsules | Morphine Tablet | Total |
|---|---|---|---|
| Mean | 43.44 ± 11.06 | 43.29 ± 10.53 | 43.37 ± 10.77 |
| Sex: Female, Male(Participants) | OxyNorm Capsules | Morphine Tablet | Total |
|---|---|---|---|
| Female | 101 | 93 | 194 |
| Male | 16 | 24 | 40 |
| Race (NIH/OMB)(Participants) | OxyNorm Capsules | Morphine Tablet | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 116 | 117 | 233 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | OxyNorm Capsules | Morphine Tablet | Total |
|---|---|---|---|
| China | 117 | 117 | 234 |
| Electrocardiogram test(Participants) | OxyNorm Capsules | Morphine Tablet | Total |
|---|---|---|---|
| normal | 88 | 76 | 164 |
| abnormal, not clinical significant | 29 | 34 | 63 |
| abnormal,clinical significant | 0 | 5 | 5 |
| America Society of Anesthesiologist classification(Participants) | OxyNorm Capsules | Morphine Tablet | Total |
|---|---|---|---|
| P1(Class I) | 61 | 57 | 118 |
| P2(Class II) | 56 | 60 | 116 |
No study locations are listed for this record.
The record gives a start of Jul 2011, a primary completion of Jun 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone
Mundipharma (China) Pharmaceutical Co. Ltd →